Monopar Therapeutics (MNPR) stock
MNPRNasdaqPharmaceutical PreparationsFiscal year ends December 31
$71.06−0.91 (-1.26%)
Close on Nov 17, 2026Market cap $476.97MP/E –Yield –
Monopar Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Monopar Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $14.78M, up 3.5% year over year. For fiscal 2025 it was $9.90M, down 23.8% from the year before. The highest annual figure on record is $13.01M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.90M | -23.8% |
| FY2024 | Dec 31, 2024 | $13.01M | +132.2% |
| FY2023 | Dec 31, 2023 | $5.60M | -26.2% |
| FY2022 | Dec 31, 2022 | $7.59M | +16.9% |
| FY2021 | Dec 31, 2021 | $6.49M | +59.7% |
| FY2020 | Dec 31, 2020 | $4.07M | +106.5% |
| FY2019 | Dec 31, 2019 | $1.97M | +10.9% |
| FY2018 | Dec 31, 2018 | $1.77M | +89.7% |
| FY2017 | Dec 31, 2017 | $935.32K | +233.6% |
| FY2016 | Dec 31, 2016 | $280.36K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $4.77M | +175.5% |
| Q1 FY2026 | Mar 31, 2026 | $3.49M | +112.2% |
| Q4 FY2025 | Dec 31, 2025 | $3.94M | -60.3% |
| Q3 FY2025 | Sep 30, 2025 | $2.59M | +163.1% |
| Q2 FY2025 | Jun 30, 2025 | $1.73M | +53.0% |
| Q1 FY2025 | Mar 31, 2025 | $1.64M | +70.1% |
| Q4 FY2024 | Dec 31, 2024 | $9.92M | +858.4% |
| Q3 FY2024 | Sep 30, 2024 | $984.28K | -25.2% |
| Q2 FY2024 | Jun 30, 2024 | $1.13M | -29.1% |
| Q1 FY2024 | Mar 31, 2024 | $966.11K | -41.6% |
| Q4 FY2023 | Dec 31, 2023 | $1.04M | -50.8% |
| Q3 FY2023 | Sep 30, 2023 | $1.32M | -24.0% |
| Q2 FY2023 | Jun 30, 2023 | $1.59M | -23.3% |
| Q1 FY2023 | Mar 31, 2023 | $1.65M | -1.5% |
| Q4 FY2022 | Dec 31, 2022 | $2.10M | +6.1% |
| Q3 FY2022 | Sep 30, 2022 | $1.73M | -5.2% |
| Q2 FY2022 | Jun 30, 2022 | $2.08M | +40.8% |
| Q1 FY2022 | Mar 31, 2022 | $1.68M | +39.0% |
| Q4 FY2021 | Dec 31, 2021 | $1.98M | +21.5% |
| Q3 FY2021 | Sep 30, 2021 | $1.83M | +45.5% |
| Q2 FY2021 | Jun 30, 2021 | $1.48M | +77.3% |
| Q1 FY2021 | Mar 31, 2021 | $1.21M | +250.4% |
| Q4 FY2020 | Dec 31, 2020 | $1.63M | +179.6% |
| Q3 FY2020 | Sep 30, 2020 | $1.26M | +471.3% |
| Q2 FY2020 | Jun 30, 2020 | $832.50K | +152.8% |
| Q1 FY2020 | Mar 31, 2020 | $344.41K | -58.8% |
| Q4 FY2019 | Dec 31, 2019 | $583.78K | +12.1% |
| Q3 FY2019 | Sep 30, 2019 | $219.85K | -27.6% |
| Q2 FY2019 | Jun 30, 2019 | $329.29K | +8.4% |
| Q1 FY2019 | Mar 31, 2019 | $835.60K | +82.8% |
| Q4 FY2018 | Dec 31, 2018 | $520.98K | +68.4% |
| Q3 FY2018 | Sep 30, 2018 | $303.68K | +68.1% |
| Q2 FY2018 | Jun 30, 2018 | $303.68K | -2.5% |
| Q1 FY2018 | Mar 31, 2018 | $457.14K | +241.8% |
| Q4 FY2017 | Dec 31, 2017 | $309.32K | – |
| Q3 FY2017 | Sep 30, 2017 | $180.68K | – |
| Q2 FY2017 | Jun 30, 2017 | $311.59K | – |
| Q1 FY2017 | Mar 31, 2017 | $133.74K | – |
See a number that looks wrong?